The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Studies Identify Possible Markers of Early Systemic Sclerosis

New Studies Identify Possible Markers of Early Systemic Sclerosis

August 16, 2019 • By Bryn Nelson, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Next Steps

To further understand the respective roles of the macrophage cells, Dr. Cutolo says his group is conducting follow-up studies on rheumatoid arthritis characterized by the prevalence of pro-inflammatory M1 cells.

You Might Also Like
  • GI Disease in Early Systemic Sclerosis Associated with Worse Outcomes
  • Markers for Severe Gastrointestinal Dysmotility in Systemic Sclerosis
  • Low Blood Pressure Increases Risk of Death in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Explore This Issue
August 2019
Also By This Author
  • What the Affordable Care Act Means for Rheumatology

“We would like to try to reduce the M1 polarization and possibly increase the M2 polarization,” he says. The work may help reveal the differing M1-M2 balance between the pro-inflammatory and anti-inflammatory cytokines in both diseases.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The CD86 marker, which is more closely associated with M1 cells but also up-regulated in M2 cells, for example, has been linked to both rheumatoid arthritis and systemic sclerosis macrophages. A CD86 blocker consisting of the fusion protein CTLA4-Ig (abatacept) has been a classical target for rheumatoid arthritis therapy. In a recent ACR presentation, Dr. Cutolo’s group suggests the biologic drug may benefit systemic sclerosis patients as well.

Combination therapies often include immune suppressors such as low-dose methotrexate or rituximab to deplete the C19 B lymphocytes that produce disease-promoting autoantibodies. Vasodilators plus vasoconstrictor inhibitors (such as endothelin-1 receptor blockers) can help promote blood flow and drug diffusion into tissues.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers have long known that gluco­corticoids can induce expression of the CD163 marker. In their study on lung involvement, Dr. Cutolo and colleagues analyzed the patients’ treatment regimens and noted that glucocorticoid use increased M2 polarization.

“This is probably one of the reasons why we don’t use glucocorticoids in systemic sclerosis too much—especially in high doses for overt disease—because it may induce a worsening of the disease,” Dr. Cutolo says.

He also says rheumatologists don’t yet know how other therapies in the existing and developing arsenal may alter the percentages of circulating macrophages, however. “So we have to treat patients with different drugs and we will see what happens.”4

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Pioli cautions that it will be important to verify the study results with data from tissue macrophages, in part because the activation of macrophages is influenced by their local microenvironment. Researchers know that macrophages in different anatomical contexts, even within the same person, can have different activation profiles.

The low recovery rate of macrophages from human skin, she concedes, can present a major challenge for conducting functional studies. “But I think complementing these data with things like single-cell sequence data from primary tissue macrophages will be really important,” says Dr. Pioli. “And we can certainly use these peripheral blood cells as models based on what we know about their activation.”

If verified, the resulting signature of up-regulated markers could provide a better indicator of active systemic sclerosis, Dr. Pioli says. “I think it will be important for things like sub-setting patients, and down the line for potentially devising differential therapeutics for different patients based on their gene expression profile of the macrophages.”

Those goals are likely to be aided by a growing pool of macrophage cell surface markers. “I think that there are many, many more. This is really just scratching the surface,” Dr. Pioli says. “We can get a much more defined picture, I think, because this is just a very general survey, but I think it’s important because nobody’s done it.” 

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Research Reviews, Scleroderma Tagged With: inflammatory markers, macrophage, systemic sclerosis (SSc)Issue: August 2019

You Might Also Like:
  • GI Disease in Early Systemic Sclerosis Associated with Worse Outcomes
  • Markers for Severe Gastrointestinal Dysmotility in Systemic Sclerosis
  • Low Blood Pressure Increases Risk of Death in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
  • Recent Trials Investigated Targeted Therapies for Systemic Sclerosis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.